Milestones and Key Events | Expected Date | |
Un-blinded rapid virologic response (RVR) and early virologic response (EVR) data from the on-going Phase 2b study of RG7227 plus SOC (un-boosted 12-week regimens) | Late Q1 or early Q2 2010 (updated guidance with additional data reported) | |
Initiation of INFORM-2 program (ritonavir-boosted RG7227 plus RG7128) | Q1 2010: Timing subject to change due to integration of new ritonavir boosting strategy
| |
Initiation of longer duration DAA study to evaluate SVR (ritonavir boosted) | Q2 2010: Timing subject to change due to integration of new ritonavir boosting strategy
| |
Initiation of Phase 2b study of ritonavir-boosted RG7227 plus SOC | Q3 2010 (new study) | |
